Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Chemomab Therapeutics Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -73.21%, provide a clear picture of how effectively CMMB converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CMMB competes directly with industry leaders such as SRXH and QNCX. With a market capitalization of $9.42M, it holds a leading position in the sector. When comparing efficiency, CMMB's gross margin of N/A stands against SRXH's 23.35% and QNCX's N/A. Such benchmarking helps identify whether Chemomab Therapeutics Ltd is trading at a premium or discount relative to its financial performance.
